The management of severe preeclampsia with intravenous magnesium sulphate, hydralazine and central venous catheterization.
A prospective study of patients with severe preeclampsia managed by magnesium sulphate infusion for eclampsia prophylaxis, hydralazine infusion for vasodilatation and central venous catheterization for fluid monitoring is reported. In this preliminary report of 46 patients, there was no episode of eclampsia following treatment, no maternal death, and hypertension was well controlled in all patients. Of the 51 babies born, there were 7 stillbirths, and 4 neonatal deaths; 6 of the 7 stillbirths were less than 30 weeks' gestation, and 23 of the 46 patients were delivered by Caesarean section.
Reti
L L
LL
Division of Obstetrics, Royal Women's Hospital, Melbourne.
Ross
A
A
Kloss
M
M
Paull
J
J
Markman
L
L
D000208:Acute Disease; D002405:Catheterization, Central Venous; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
D006830:Hydralazine; D008278:Magnesium Sulfate